EBI2 receptor as a new myelin repair therapy in multiple sclerosis.

2022/47/D/NZ3/02613

Keywords

Descriptors

  • NZ3_006: Neurobiologia komórkowa
  • NZ3_005: Neurobiologia molekularna
  • NZ4_007: Neurofizjologia

Panel

NZ3 – Cellular and developmental biology: cell biology, developmental biology, ageing biology, neurobiology

Host institution

Gdański Uniwersytet Medyczny, Wydział Lekarski

Voivodeship: pomorskie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr hab. Aleksandra Rutkowska

Number of co-investigators in the project: 3

Call

SONATA 18 – announced on 2022-07-15

Amount awarded
1 707 496 PLN
Project start date
2023-12-01
Project end date
2026-11-30
Project duration
36 months (the same as in the proposal)
Project status
Pending project

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

Publication in academic press/journals (1)

  1. Accelerated remyelination and immune modulation by the EBI2 agonist 7α,25-dihydroxycholesterol analogue in the cuprizone model

    Authors:
    Klaudia Konieczna-Wolska, Fionä Caratis, Mikołaj Opiełka, Karol Biernacki, Krzysztof Urbanowicz, Joanna Klimaszewska, Piotr Pobiarzyn, Oliwier Krajewski, Sebastian Demkowicz, Ryszard T. Smoleński, Bartosz Karaszewski, Klaus Seuwen, Aleksandra Rutkowska
    Academic press:
    Biomedicine & Pharmacotherapy (year: 2024, volume: 181, pages: 117653), Publisher: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.biopha.2024.117653 – link to the publication

« New search

Graphic design and implementation: Jakub Piotrowski